Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | YAP1 | P46937 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17822339 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BALDH1A1ALOX15YAP1 | |
| SCHEMBL2059183 | 0.85 | ITGB3 (0.70) | ITGB3ITGA2BP2RX7 | |
| SCHEMBL3637824 | 0.85 | MEN1 (0.49) | ITGB3ITGA2BALDH1A1ALOX15YAP1 | |
| SCHEMBL3637818 | 0.85 | MEN1 (0.49) | ITGB3ITGA2BALDH1A1ALOX15YAP1 | |
| SCHEMBL17833223 | 0.84 | CTRB1 (0.60) | ALDH1A1YAP1CYP3A4TSHRMEN1 | |
| SCHEMBL19639228 | 0.84 | CTRB1 (0.60) | ALDH1A1YAP1CYP3A4TSHRMEN1 | |
| SCHEMBL2059100 | 0.84 | P2RX7 (0.59) | ITGB3ITGA2BYAP1P2RX7 | |
| SCHEMBL2406036 | 0.82 | ALDH1A1 (0.65) | ITGB3ITGA2BALDH1A1ALOX15CYP3A4 | |
| SCHEMBL8569421 | 0.82 | ALDH1A1 (0.65) | ITGB3ITGA2BALDH1A1ALOX15CYP3A4 | |
| SCHEMBL19678646 | 0.82 | MMEL1 (0.49) | ALDH1A1YAP1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348375-A1 | DISLODGEMENT AND RELEASE OF HSC FROM THE BONE MARROW STEM CELL NICHE USING ALPHA9 INTEGRIN ANTAGONISTS | COMMW SCIENT IND RES ORG (AU) | 2017-12-07 | — | — | US | disclosed |
| EP-3229797-A1 | DISLODGEMENT AND RELEASE OF HSC FROM THE BONE MARROW STEM CELL NICHE USING ALPHA9 INTEGRIN ANTAGONISTS | Commonwealth Scientific and Industrial Research Organisation (AU) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016090403-A1 | DISLODGEMENT AND RELEASE OF HSC FROM THE BONE MARROW STEM CELL NICHE USING ALPHA9 INTEGRIN ANTAGONISTS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348375-A1 | DISLODGEMENT AND RELEASE OF HSC FROM THE BONE MARROW STEM CELL NICHE USING ALPHA9 INTEGRIN ANTAGONISTS | CXCL12, BST2, CCR9 | ITGB3 13/4885ITGA2B 8/4885ALDH1A1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.